Pfizer statement: NICE appraisal consultation document for MYLOTARG™▼

 

Craig Eagle, Head of Oncology, Pfizer UK said: “We are pleased that NICE has recognised the important impact that gemtuzumab ozogamicin could have on people diagnosed with acute myeloid leukaemia in the UK, and we welcome today’s preliminary decision to recommend the medicine for patients with favourable or unknown cytogenetics. However, this provisional recommendation currently excludes 65% of the eligible patient population and so we will continue working with NICE to help ensure that all patients who are eligible to benefit from this treatment are able to access it once a final recommendation is issued.”